Founded in 1984, Kensey Nash Corporation is a medical technology company that develops and manufactures absorbable biomaterials-based products with applications in the cardiology, orthopedics, spine, drug and biologics delivery, periodontal/dental, surgical and wound-care markets. Its flagship product, the Angio-Seal vascular closure device, is designed to seal and close femoral artery punctures made during diagnostic and therapeutic cardiovascular catheterizations. The company also markets its proprietary TriActiv embolic protection system, a device designed to prevent microparticulates from traveling downstream during the treatment of diseased coronary saphenous vein bypass grafts. This system utilizes active flushing and extraction to remove debris from the vessel after a treatment procedure. The company also develops various bone graft substitutes fabricated from collagen, synthetic polymers and composite biomaterials. Kensey Nash Corporation maintains its United States headquarters in Exton, Penn., and its European headquarters in Germany.